Zanubrutinib
|
|
- CAS-Nr.
- 1691249-45-2
- Englisch Name:
- Zanubrutinib
- Synonyma:
- Zebutinib;anubrutinib;Zanubrutinib;Zanubritinib;Zanmubrutinib;Zanubtutinib AP;Zanubrutinib API;The BTK inhibitor;BGB-3111(Zanubrutinib);Zanubrutinib (BGB-3111)
- CBNumber:
- CB93361383
- Summenformel:
- C27H29N5O3
- Molgewicht:
- 471.55
- MOL-Datei:
- 1691249-45-2.mol
|
Zanubrutinib Eigenschaften
- Siedepunkt:
- 713.4±60.0 °C(Predicted)
- Dichte
- 1.33±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- L?slichkeit
- DMSO:99.67(Max Conc. mg/mL);211.36(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);21.21(Max Conc. mM)
DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.34(Max Conc. mM)
Ethanol:33.33(Max Conc. mg/mL);70.68(Max Conc. mM)
- Aggregatzustand
- A solid
- pka
- 15.35±0.40(Predicted)
- Farbe
- White to off-white
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
|
|
Sicherheit |
P261 |
Einatmen von Staub vermeiden. |
P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Zanubrutinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Zanubrutinib, a second-generation BTK inhibitor discovered and developed by BeiGene in China, has been approved by the FDA (in 2019) for treating chronic lymphocytic leukemia (CLL) and certain other indications. Zanubrutinib has lower toxicity and better efficacy than ibrutinib. It is in direct competition with AstraZeneca’s acalabrutinib for the $12 billion blood cancer market currently dominated by the first-in-class BTK inhibitor ibrutinib.
Verwenden
Zanubrutinib is classified as a Bruton''s tyrosine kinase inhibitor. Zanubrutinib is a medication for the treatment of adults with mantle cell lymphoma.
Stoffwechsel
Zanubrutinib showed a mean terminal elimination half-life of approximately 2–4 h (160 or 320 mg, QD) and an estimated oral bioavailability of 15%, relative to 3.9% (fasting state) for ibrutinib. Zanubrutinib is primarily eliminated hepatically via CYP3A4, but its metabolites have not been characterized.
Zanubrutinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Zanubrutinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 128)Lieferanten
1691249-45-2()Verwandte Suche:
- Zanubrutinib
- anubrutinib
- BGB-3111(Zanubrutinib)
- The BTK inhibitor
- Zanubrutinib (BGB-3111)
- BGB-3111;ZANUBRUTINIB;BGB 3111;BGB3111
- (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
- Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-, (7S)-
- Zanubrutinib-D5Q: What is
Zanubrutinib-D5 Q: What is the CAS Number of
Zanubrutinib-D5
- ZanubrutinibQ: What is
Zanubrutinib Q: What is the CAS Number of
Zanubrutinib
- Benzoicacid,3,9-bis(phenylmethoxy)-
- Btk,zanubrutinib,BGB3111,Inhibitor,inhibit,BGB 3111,Bruton tyrosine kinase
- (7S)-2-(4-phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4H,5H,6H,7H-pyrazolo[1,5-a]pyrimidine-3-carboxamide
- Zanubrutinib API & all impurites
- Zanubrutinib API
- Zanmubrutinib
- Zebutinib
- Zanubtutinib AP
- Zanubritinib
- 1691249-45-2
- API